Overview

Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-30

Target enrollment:

Participant gender:

Summary

The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination therapy compared to standard therapy (methotrexate, mycophenolate mofetil) for 56 weeks.

Phase:

PHASE3

Details

Lead Sponsor:

National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland

Collaborator:

Medical Research Agency, Poland

Treatments:

Methotrexate
Mycophenolic Acid
nintedanib
Standard of Care
tocilizumab